Eli Casdin

Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information.

Cooper Hill Partners LLC is a New York City-based hedge fund manager.

Genomatica, Inc. designs and develops biotechnology products. It offers metabolic engineering for renewable production of commodity chemicals. The company was founded by Bernhard O. Palsson and Christophe H. Schilling in 1998 and is headquartered in San Diego, CA.

AllianceBernstein LP (AB) is a SEC-registered investment advisor and mutual fund manager headquartered in Nashville, Tennessee. Founded in 2000, the firm is owned by Equitable Financial Life Insurance Co., ultimately held by Equitable Holdings, Inc. (NYSE: EQH). AB provides investment advice to investment companies, pension and profit-sharing plans, banks and thrift institutions, trusts, estates, government agencies, charitable organizations, individuals, corporations and other business entities.

SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO.

SynapDx Corp. operates as a laboratory services company which develops a blood-based test for the early detection of autism spectrum disorder. It provides laboratory testing services to physicians who evaluate children for developmental disorders with the initial goal of enabling earlier detection of autism. The company was founded by Stanley N. Lapidus, Jeffrey R. Luber, Graham Gardner and Patrick A. Anquetil in 2010 and is headquartered in Lexington, MA.

New York Genome Center operates as an independent, nonprofit academic research institution that provides genomic research. It provides research on neurodegenerative disease, neuropsychiatric disease, and cancer. The company was founded in 2011 and is headquartered in New York, NY.

Casdin Capital LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Eli Casdin in 2012. They provide investment management services to pooled investment vehicle, or more specifically, a private investment fund, the securities of which are offered to certain qualified investors on a private placement basis.

Verana Health, Inc. engages in the development of software solutions for remote patient monitoring and data analytics. It focuses on bridging the gap between healthcare providers and patients with mobile tests. The company was founded by Mark S. Blumenkranz and Daniel V. Palanker in 2008 and is headquartered in San Francisco, CA.

Imagen Technologies, Inc. operates as a medical technology company that develops and offers devices for the prevention of diagnostic errors. The company was founded by Alexander Dresner, Robert Lindsey, Thomas Stuart Hotchkiss and Sumit Chopra in 2015 and is headquartered in New York, NY.

Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in San Francisco CA.

Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA.

Casdin Capital /Private Equity/ (Casdin Capital) is a private equity/venture capital subsidiary of Casdin Capital LLC founded in 2012 by Eli Casdin. The firm is headquartered in New York.

Genome Medical Holding Co. operates tele genomics platform which allows genetic experts to consult with patients and physicians across the country. The firm specializes in genomics, genetics, precision medicine, medical practice, personalized medicine, genetic counseling, DNA and genome. The company was founded by Lisa J. Alderson, Robert C. Green and Randal W. Scott in 2016 and is headquartered in South San Francisco, CA.

Gene Matters LLC engages in the provision of genetic counseling services. It serves genetic counselors, management team, and advisors. The company was founded by Jill Davies in 2016 and is headquartered in Minneapolis, MN.

Casdin Partners Offshore Ltd. operates as a hedge fund. The company is headquartered in George Town, Cayman Islands.

DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France.

Paige Ai, Inc. engages in revolutionizing pathology and strengthen lynchpin of medical diagnostics with quantitative, computational technology, fusing machine learning, and human expertise. It involves in building an artificial intelligence to change clinical diagnosis and treatment of cancer. The company is headquartered in New York, NY.

Cedilla Therapeutics, Inc. operats as a biotechnology company. It engages in discovering and exploiting insights into protein stability. The company was founded by Alan D. D?Andrea, Steve Gygi, Matthew P. Jacobson, William G. Kaelin, Jr. and Jack Taunton on September 6, 2017 and is headquartered in Cambridge, MA.

Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA.

Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA.

Sexton Biotechnologies, Inc. operates biotechnology company which develops and sales of bio-production tools for cell and gene therapy. The company is headquartered in Indianapolis, IN.

EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA.

Prominex, Inc. manufactures molecular diagnostic assays for infectious disease testing. The company was founded by Paul Thomas and Paul Gargan in 2017 and is headquartered in San Diego, CA.

C2i Genomics, Inc. is engaged in the research and development on cancer. It provides ultrasensitive test for cancer. The company was founded by Asaf Zviran and Ezra Sofer in 2019 and is headquartered in New York, NY.

CM Life Sciences, Inc. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on July 10, 2020 and is headquartered in New York, NY.

GeneMatters LLC operates as a digital technology platform that provides genomic medicine delivery services. The company is based in Minneapolis, MN.

CM Life Sciences II, Inc. is a blank check company, which engages in seeking a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on December 15, 2020 and is headquartered in New York, NY.

CM Life Sciences III, Inc. was operated as a blank check company formed as a Delaware corporation for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on January 25, 2021 and it was headquartered in New York, NY.

Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA.

Mnemo Therapeutics SAS is a French biotechnology company that develops cell therapies to create accessible cures for cancer patients. The company is based in Paris, FR, and has subsidiaries in the United States. The company applies a novel approach to cell therapy using its enfinit platform, a groundbreaking drug discovery engine. Mnemo is committed to addressing the challenges in the field of immuno-oncology, such as a lack of cancer-specific targets, long-term persistence, and sensitivity. The company aims to engineer the future of immunotherapies to transform the lives of people with cancer by discovering novel cancer-specific targets and boosting immune activity to treat solid tumors. The company was founded in 2019 by Alain Maïore and Michel Sadelain. Robert LaCaze has been the CEO of the company since 2022.

Leyden Labs develops preventive medicines that target respiratory viruses. The private company is based in Leiden, Netherlands.

IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.